EGFR/AURKB-IN-1
EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR and AURKB with IC50s of 0.07 and 1.1, respectively. EGFR/AURKB-IN-1 occupies the hydrophobic region I or the αC-helix out pocket of EGFR and the back pocket of AURKB, inhibiting the growth, division and metastasis of tumor cells, thus can be used for cancer research[1].
Product Specifications
CAS Number
[3008543-34-5]
UNSPSC
12352005
Target
Aurora Kinase; EGFR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/egfr-aurkb-in-1.html
Purity
99.43
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CN1N=CC=C1C2=CC3=C(N=CN=C3N2)NC4=CC=C(C=C4)OCC5=CC=CC=C5
Molecular Formula
C23H20N6O
Molecular Weight
396.44
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Browse additional items from our catalog
SPI1 CRISPRa sgRNA lentivector (set of three targets)(Human)
NKp46, Natural Cytotoxicity Receptor (NCR NKp46, CD335, Lymphocyte Antigen 94, Ly94, Natural Cytotoxicity Triggering Receptor 1, NCR1, NCT1, Natural Killer Cell Activating Receptor NKp46, NK Cell Activating Receptor) (HRP)
L-α-Phosphatidylinositol-4,5-bisphosphate ammonium